Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722176 · ClinicalTrials.gov registry record · Phase 2
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
A Phase 2 study, sponsored by BioLineRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00722176: Completed Phase 2 study, sponsored by BioLineRx.
NCT00722176 is a Phase 2 study that has completed, run by BioLineRx. The registered enrollment target is 220 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00722176, a Phase 2 study, has completed, sponsored by BioLineRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously Treated In Study Bl-1020 Iib For A Maximum Of Six Weeks With Bl-1020 (High Dose, Low Dose), Risperidone Or Placebo
Interventions
- DRUG risperidone
- DRUG BL-1020
- DRUG BL-1020 10-30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722176
The ClinicalTrials.gov registry entry for NCT00722176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioLineRx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which risperidone is the first listed.
NCT00722176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722176 about?
NCT00722176 is a clinical study titled "Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020". A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously Treated In Study Bl-1020 Iib For A Maximum Of Six Weeks With Bl-1020 (High ...
What is the current status of trial NCT00722176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2008-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00722176?
The interventions under investigation include: risperidone (DRUG), BL-1020 (DRUG), BL-1020 10-30 mg (DRUG).
Who is sponsoring clinical trial NCT00722176?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.